Lyell Immunopharma (LYEL) Income from Continuing Operations (2020 - 2025)
Historic Income from Continuing Operations for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$34.0 million.
- Lyell Immunopharma's Income from Continuing Operations rose 2369.33% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.6 million, marking a year-over-year decrease of 7161.37%. This contributed to the annual value of -$334.7 million for FY2024, which is 4971.13% down from last year.
- Lyell Immunopharma's Income from Continuing Operations amounted to -$34.0 million in Q3 2025, which was up 2369.33% from -$43.9 million recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's Income from Continuing Operations registered a high of -$11.3 million during Q4 2022, and its lowest value of -$196.2 million during Q4 2024.
- In the last 5 years, Lyell Immunopharma's Income from Continuing Operations had a median value of -$52.4 million in 2023 and averaged -$57.0 million.
- Per our database at Business Quant, Lyell Immunopharma's Income from Continuing Operations soared by 7600.13% in 2022 and then tumbled by 36266.0% in 2023.
- Lyell Immunopharma's Income from Continuing Operations (Quarter) stood at -$47.2 million in 2021, then surged by 76.0% to -$11.3 million in 2022, then crashed by 362.66% to -$52.4 million in 2023, then crashed by 274.31% to -$196.2 million in 2024, then skyrocketed by 82.68% to -$34.0 million in 2025.
- Its Income from Continuing Operations stands at -$34.0 million for Q3 2025, versus -$43.9 million for Q2 2025 and -$53.5 million for Q1 2025.